Trial 10M-23-4


A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants with Unresectable or Metastatic Melanoma Resistant to Checkpoint Inhibitors and After BRAF-MEK Targeting Therapy in Participants with BRAF Mutated Melanoma

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Autologous Bone Marrow Transplant, Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Gino In, M.D.
Other Trial Staff:  Mary Ordaz, D.M., Aida Lozada, Coordinator, Niranjan Bhatt, D.M., Sreebharathy Venkatesh, D.M., Sana Mutalib, Coordinator, Anisa Sandin, Coordinator, Thomas Won, Coordinator, Marie-Laure Gollier, D.M., Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.